Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980041 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
A Phase 2 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT03980041 is a Phase 2 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 49 participants.
The verdict
NCT03980041, a Phase 2 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
Interventions
- DRUG Nivolumab
- DRUG Placebos
- DRUG IPI-549 (eganelisib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03980041
The ClinicalTrials.gov registry entry for NCT03980041 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infinity Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03980041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03980041 about?
NCT03980041 is a clinical study titled "Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)". The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
What is the current status of trial NCT03980041?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2019-09-25. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT03980041?
The interventions under investigation include: Nivolumab (DRUG), Placebos (DRUG), IPI-549 (eganelisib) (DRUG).
Who is sponsoring clinical trial NCT03980041?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.